High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. 1995

C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
Department of Pathology, University of Pittsburgh School of Medicine, Pennsylvania, USA.

Lack of disease in long-term nonprogressors with human immunodeficiency virus type 1 (HIV-1) infection was strongly associated with very low copy numbers of HIV-1 DNA and RNA in peripheral blood mononuclear cells and plasma and the presence of high levels of anti-HIV-1 CD8+ memory cytotoxic T lymphocytes specific for Gag, Pol, and Env, compared with levels present in intermediate and advanced progressors. CD8+ memory cytotoxic T lymphocytes may have an important role in controlling HIV-1 replication and preventing disease in long-term nonprogressors.

UI MeSH Term Description Entries
D007156 Immunologic Memory The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus. Immune Memory,Immunological Memory,Memory, Immunologic,Immune Memories,Immunologic Memories,Immunological Memories,Memory, Immune,Memory, Immunological
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
September 1999, AIDS research and human retroviruses,
C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
January 1998, Viral immunology,
C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
May 2021, Cells,
C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
May 1999, The Journal of infectious diseases,
C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
December 2003, Journal of medical virology,
C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
January 2005, Clinical and diagnostic laboratory immunology,
C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
November 1997, The Journal of infectious diseases,
C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
December 2010, BMC infectious diseases,
C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
December 2004, Zhonghua yi xue za zhi,
C Rinaldo, and X L Huang, and Z F Fan, and M Ding, and L Beltz, and A Logar, and D Panicali, and G Mazzara, and J Liebmann, and M Cottrill
January 1994, Cellular and molecular biology (Noisy-le-Grand, France),
Copied contents to your clipboard!